

## 2<sup>nd</sup> European CAR T Cell Meeting

### Abstract submission guidelines

#### Introduction

The abstract submission guidelines of the 2<sup>nd</sup> European CAR T Cell Meeting are intended to provide clear instructions before submitting an abstract. **You are kindly requested to carefully read the guidelines stated below.**

The EHA and the Scientific Program Committee (SPC) of the meeting maintain the right to reject any abstract that does not meet below requirements.

#### Table of Contents

|  |   |
|--|---|
| Submission guidelines .....            | 2 |
| Timelines .....                        | 3 |
| Review, selection and publication..... | 3 |
| Topics .....                           | 3 |

## Submission guidelines

The submitted abstracts should fully adhere to the guidelines below.

### General guidelines

1. Abstracts should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.
2. The SPC assumes all presenting authors have proficiency in English, thus are able to present and respond to questions.
3. In clinical studies, please state whether informed consent was obtained.
4. The title and text may not contain trade names.
5. If off label use of drugs was involved, please state this clearly.
6. Withdrawal policy: If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to the EHA Executive Office ([scientificmeetings@ehaweb.org](mailto:scientificmeetings@ehaweb.org)) before **November 15, 2019**. Consequently the abstract will not be presented nor published.
7. The Scientific Program Committee encourages the submission of original scientific material unpublished at the time of the abstract submission deadline:
  - a. Abstracts submitted to regional or national hematology meetings can be submitted to the Scientific Meeting for inclusion in the program;
  - b. Abstracts submitted to large international meetings which are organized in the same period as the EHA Scientific Meeting (December - February) are allowed to be submitted to the meeting.
  - c. Abstracts submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract submission field.
8. Submitted abstracts are considered embargoed from the time of submission.
9. Please do not submit the same study in multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
10. Similarly, abstracts or (close) copies, may not be submitted under more than 1 category.

## Timelines

|                   |                                       |
|-------------------|---------------------------------------|
| August 1, 2019    | Start abstract submission             |
| November 15, 2019 | Deadline abstract submission          |
| December 1, 2019  | Notification of allocation to authors |

## Review, selection and publication

1. All submitted abstracts will be reviewed by the Scientific Program Committee of the 2<sup>nd</sup> European CAR T Cell Meeting.
2. Abstracts may be selected for
  - a. oral presentation
  - b. poster presentation
  - c. rejection
3. The submitting author will receive a confirmation of acceptance for oral presentation, poster presentation, or a notice of rejection, by e-mail at or before **December 1, 2019**.
4. Oral and poster presenters will be informed about the date and time of the session and will receive guidelines for their presentation.

## Topics

Please select the most appropriate topic during the abstract submission:

### CAR-based therapeutic approaches for

1. Acute lymphoblastic leukemia - Biology & Translational Research,
2. Acute lymphoblastic leukemia - Clinical,
3. Acute myeloid leukemia - Biology & Translational Research,
4. Acute myeloid leukemia - Clinical,
5. Chronic lymphocytic leukemia and related disorders - Biology & Translational Research,
6. Chronic lymphocytic leukemia and related disorders – Clinical,
7. Myeloma and other monoclonal gammopathies - Biology & Translational Research,
8. Myeloma and other monoclonal gammopathies - Clinical,
9. Hodgkin lymphoma - Biology & Translational Research,
10. Hodgkin lymphoma - Clinical,
11. Non-Hodgkin lymphoma Biology & Translational Research,
12. Non-Hodgkin lymphoma - Clinical,
13. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research,
14. Gene therapy, cellular immunotherapy and vaccination - Clinical,
15. Clinical implementation of immune effector cell based therapies, including combinatorial approaches with other immune therapies,
16. Solid tumor and autoimmune disorders, and
17. Medico-economics, regulatory and patients acceptance aspects of CAR T cell therapies.